CLASS II Device recall · Reported 9 Jun 2021 · FDA Enforcement Report

Synapse Cardiovascular (Synapse CV) recalled

Fujifilm Medical Systems U.S.A is recalling Synapse Cardiovascular (Synapse CV), distributed nationwide in the US. The recall was initiated on 30 Apr 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesSoftware Versions: 6.0 to 6.2.1
Quantity recalled44 US and 4 OUS

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1775-2021
FDA event ID
87938
Recalling firm
Fujifilm Medical Systems U.S.A, Lexington, MA
Classification
Class II
Status
Terminated
Recall initiated
30 Apr 2021
FDA classified
2 Jun 2021
Reported
9 Jun 2021
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Device Malfunction

Timeline

30 Apr 2021Recall initiated by company
2 Jun 2021Classified by FDA+33 days
9 Jun 2021Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Software versions 6.0.4 to 6.2.1 using Advanced Reporting -possibility that a previously assigned internal patient database ID can be reused for a new patient. It was discovered that this value does not increase when a patient merge activity is executed in a specific sequence

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Synapse Cardiovascular (Synapse CV). Software Versions: 6.0 to 6.2.1 The Synapse Cardiovascular image is a management and reporting system

Where it was distributed

Worldwide distribution - US Nationwide distribution and the countries of Canada, Bermuda, Israel, Hadassah Medical Center.

Nationwide

Questions about this recall

Is Synapse Cardiovascular (Synapse CV) recalled?

Yes. Fujifilm Medical Systems U.S.A recalled Synapse Cardiovascular (Synapse CV) on 30 Apr 2021. The recall is Class II and its status is Terminated. Recall number Z-1775-2021.

Why was it recalled?

Software versions 6.0.4 to 6.2.1 using Advanced Reporting -possibility that a previously assigned internal patient database ID can be reused for a new patient. It was discovered that this value does not increase when a patient merge activity is executed in a specific sequence

Which lots are affected?

Software Versions: 6.0 to 6.2.1

Where was it sold?

Worldwide distribution - US Nationwide distribution and the countries of Canada, Bermuda, Israel, Hadassah Medical Center.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Fujifilm Medical Systems U.S.A

All 37

Other Heart & Vascular Devices recalls

All 6,199